Status:
COMPLETED
Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Spinal Fusion Acquired
Spinal Stenosis
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Major lumbar spine surgery causes inflammation, soreness and swelling that can delay discharge from the hospital. Dexmedetomidine (DEX) has been shown to have anti-inflammatory effects. This study wil...
Detailed Description
Inflammation is a two-edged sword, one edge essential for healing, the other potentially delaying recovery. There is evidence that modest attenuation of the initial course of the inflammatory response...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists (ASA) Classification I - III
- Scheduled for Open Posterior Lumbar Fusion over 3+ (bony) levels
Exclusion
- Allergy to dexmedetomidine
- Cardiac disease with reduced ejection fraction \< 30%
- History of cirrhosis, active hepatitis or attenuated hepatic function
- Chronic use of steroids, COX-2 inhibitors, alpha-2 agonists, or statins
- Current anticoagulant therapy
- Patients requiring motor evoked potential (MEP) monitoring
- Positive pregnancy test
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT00808665
Start Date
June 1 2009
End Date
December 1 2012
Last Update
May 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232